3 days ago
2
Liudmila Chernetska
Shares of Mineralys Therapeutics (NASDAQ:MLYS) climbed ~85% on Tuesday after AstraZeneca (NASDAQ:AZN) released full results from a Phase 3 trial for baxdrostat, a blood pressure medicine similar to Mineralys’ (NASDAQ:MLYS) lead asset, lorundrostat.
The 12-week trial, BaxHTN, designed to test 2 mg
English (US) ·